Amanita muscaria — the red-capped, white-flecked fly agaric of storybook illustration — is being sold in gummies, capsules and chocolate bars alongside lion's mane and reishi, under the same “functional mushroom” banner. It does not belong in that category. FDA has placed it in its Dietary Supplement Ingredient Directory under the heading reserved for ingredients the agency has concluded do not meet the safety standard in section 402(f)(1)(B) of the Federal Food, Drug, and Cosmetic Act.
That is not a grey area, and it is not our opinion. It is an affirmative agency position about an ingredient, published in a public directory. This post explains what that position means, why the ingredient keeps turning up in a category it has no business being in, and how we screen for it as a distributor.
The short version
| Question | Answer |
|---|---|
| Is Amanita muscaria a lawful dietary ingredient? | FDA has concluded it does not meet the safety standard at FFDCA 402(f)(1)(B) and lists it accordingly. |
| Is it federally scheduled? | No. It is not a controlled substance under the Controlled Substances Act. That is a different question from whether it may lawfully be sold as a supplement. |
| Is it the same as psilocybin mushrooms? | No. Different genus, different chemistry, different legal status. |
| Is it restricted at state level? | In places, yes. Some states address hallucinogenic plants and fungi in their own statutes. Treatment varies by state and changes, so check the current rules where you are. |
| Do we carry it? | No, and we screen suppliers for it — including suppliers offering us something else entirely. |
What the Dietary Supplement Ingredient Directory actually is
FDA maintains a public directory of ingredients that have come up in dietary supplements, sorted by the concern attached to them. It is not a list of banned substances and it is not a list of approved ones. It is a running index of agency positions, and the categories mean different things. Some entries are there simply because the agency issued a safety communication about them. Others are there because FDA has determined the substance is not a dietary ingredient at all, or is excluded from the definition, or is a new dietary ingredient for which no notification was ever submitted.
The load-bearing entry for Amanita muscaria is the one for ingredients that fail the adulteration standard at 402(f)(1)(B).
Section 402(f)(1) of the FFDCA deems a dietary supplement adulterated if it presents a significant or unreasonable risk of illness or injury under the conditions of use recommended or suggested in its labeling — or, where the labeling suggests no conditions of use, under ordinary conditions of use. Subparagraph (B) is the branch that applies where the ingredient is a new dietary ingredient with inadequate information to provide reasonable assurance that it does not present such a risk.
Read plainly: FDA is not saying the paperwork is incomplete. It is saying that on the record available, this ingredient does not clear the safety bar Congress set for supplement ingredients — and that a product containing it is therefore adulterated.
How FDA acts on a position like this
Directory entries can look abstract. They are not the agency's only instrument, and it is worth knowing what the others are, because they are what turn a listed position into a compliance date for everyone selling in the category.
- Constituent updates. Short public statements FDA uses to put industry on notice of a position, often before or alongside enforcement.
- Warning letters. The agency's formal written statement that specific marketed products violate the Act. A letter is addressed to one company, but it establishes a documented awareness date for everyone else selling the same thing.
We are deliberately not citing a specific update or letter here by date and addressee. If a document is going to carry weight in your decision, you should be reading the document rather than a retailer's summary of it, and both instruments are searchable on FDA's own site. That is the same rule we apply to ourselves: what we hold, and what it does not cover, is published on our certificate of analysis page.
Why it is being pushed into the functional mushroom channel
The commercial logic is not mysterious, and it is worth stating so you can recognise the pattern the next time it repeats with a different ingredient.
It is technically a mushroom. That single fact gives it a shelf, a search term and a product photograph. “Mushroom gummies” as a category was built by lion's mane, reishi and cordyceps — ordinary dietary ingredients with no scheduling issue and no directory entry. An Amanita gummy in the same rack, in the same format, in the same font, inherits the whole category's legitimacy without earning any of it.
It sits outside the scheduling system. Its constituents of interest — ibotenic acid and muscimol — have nothing to do with the beta-glucan and polysaccharide chemistry the culinary and adaptogenic species are sold on, and nothing to do with psilocybin either. Because it is not a federally controlled substance, sellers describe it as “legal” — a word that answers the scheduling question and quietly skips the supplement question, which is the one FDA has actually answered. We are not going to describe what the ingredient does, because that description is exactly the content this corner of the market uses to sell it.
The search terms overlap. A shopper looking for a mushroom supplement and a shopper looking for something else entirely land on some of the same pages. That overlap is monetisable, and the category has monetised it.
The channel is the same one we already work in. The independent smoke-shop and online-botanical channel that carries kratom-adjacent products is the same channel that carries Amanita gummies. Suppliers there frequently run multiple labels out of one warehouse. That is precisely why a brand-level check is not enough.
Why we screen for it, and how
Botanical Blends does not manufacture anything. We carry other companies' brands, which means the only lever we have is which suppliers we do business with and what we require in writing before a product is listed. Amanita muscaria is on our hard-exclusion list, and the screen is broader than “do not stock it.”
- SKU-level exclusion. No Amanita muscaria, Amanita pantherina, muscimol or ibotenic acid product, in any format, under any brand.
- Portfolio audit of the supplier, not just the product. If a mushroom supplier offering us lion's mane also operates an Amanita line under a second label, that tells us something about the compliance function we would be relying on. It is not automatically disqualifying, but it moves the conversation from paperwork to governance.
- Blend-ingredient screening. Multi-ingredient “mushroom blend” SKUs get read ingredient by ingredient, because that is where an excluded species arrives without a headline.
- State-law screening on top of federal. Some states name fly agaric and related species in hallucinogenic-plant statutes, others do not address it at all, and the rules change. Anything we ship has to survive the strictest destination, not the most permissive one.
One detail from our own document review is worth reporting, because it cuts both ways. Some of the alkaloid panels we have read on cat's claw products in this channel list muscimol and ibotenic acid among the analytes — a legacy of the boilerplate screening panel that certain labs run by default. Wider coverage is worth having. It is also a reminder of the thing we say constantly: what matters on a certificate is which analytes are on the panel, not how confident the summary line sounds. A panel is only evidence about the compounds it looked for. We work through that in how to read a COA and apply it brand by brand in cat's claw brands in 2026.
What this post is not saying
Three limits, stated up front rather than buried.
We are not telling you this is a scheduled substance. It is not. Someone selling it is not committing a controlled-substances offence by doing so. The problem is a food-and-drug-law problem: FDA's position is that a supplement containing it is adulterated.
We are not describing what it does. This is a composition and compliance post. We do not publish effects content for ingredients we exclude, and we would rather lose the traffic.
We are not giving legal advice. If you sell in this category, read the directory entry and FDA's own enforcement records yourself and take advice on your own state exposure. Our reasoning here is the reasoning of a retailer deciding what to put on a shelf. Our general position on what we will and will not stock is summarised on our FAQ page.
Frequently Asked Questions
Is Amanita muscaria illegal to buy?
It is not a federally controlled substance, so possession is not a federal drug offence. That is a narrower answer than “legal.” FDA's position is that it does not meet the safety standard for a dietary supplement ingredient, and some states address it in their own statutes. The answer depends on where you are and what the product is sold as.
Are lion's mane and reishi affected by any of this?
No. Hericium erinaceus, Ganoderma lucidum, Cordyceps, chaga, turkey tail and maitake are ordinary dietary ingredients with no directory entry of this kind and no scheduling issue. The risk in that part of the category is product-quality fraud, not legality. See our lion's mane explainer.
Does the DEA's July 2026 kratom-alkaloid scheduling action cover Amanita?
No. Those two Notices of Intent, published in the Federal Register on July 6, 2026 as FR Doc 2026-13580 and FR Doc 2026-13581, concern kratom-related alkaloids. They are unrelated to Amanita muscaria, which is a food-and-drug-law matter rather than a scheduling one. Background on the kratom side is in is 7-OH banned.
How would I spot an Amanita product that is not labelled clearly?
Look for “muscimol” or “ibotenic acid” in the ingredient panel, for “fly agaric” as a common name, and for the red-and-white cap in the packaging art. Be wary of “mushroom blend” gummies that give a total milligram figure without naming every species. If the panel does not name every species, treat the panel as incomplete.
What do you publish about the products you do carry?
Certificates and their gaps, on our certificate of analysis page. We name the analytes a panel covers and the ones it does not, because a certificate is only evidence about the compounds it looked for.
These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Consult a qualified healthcare professional before use. Legality depends on the specific product and applicable state law — check the rules where you live. Nothing here is legal advice.